N/A N=108 Pruritus in Patients With Chronic Kidney Disease
Kidney Failure, Chronic · Pruritus
Primary: Visual Analog Scale (VAS) — 3.35 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=58 A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
Chronic Idiopathic Urticaria · Chronic Idiopathic Pruritus · Lichen Planus
Primary: Change From Baseline in Weekly Average WI-NRS at Week 8 — -4.3; -1.1; -4.3; -3.7 score on a scale — p=0.3980
Phase 2 N=10 A Study Examining the Medication Apremilast as Treatment for Chronic Itch
Itch
Primary: Absolute NRS Itch Score at Week 16 (End of Treatment) — 7; 7.5 Units on a scale
Phase 2 N=233 Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
Pruritus
Primary: Worst Itch Numeric Rating Scale 4-point Responder Rate at Week 10 — 46; 44 Participants — p=0.5861
Phase 2 N=9 Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
Pruritus
Primary: Change in Peak Pruritus Numerical Rating Score (PRNS) — -3.1 score on a scale
N/A N=21 The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease
Uremic Pruritus
Primary: Visual Analogue Scale (VAS) Score for Pruritus — -3.38; -3.53 Units on a scale — p=<0.05
Phase 2 N=20 Topical Aprepitant in Prurigo Patients
Pruritus
Primary: Pruritus by VAS (Visual Analogue Scale) — 19.7; 21.2 mm — p=0.58
N/A N=15 Acupressure in Pruritus for Atopic Dermatitis
Atopic Dermatitis
Primary: Change in Itch Intensity as Measured by a Change in Visual Analog Scale (VAS) Score — 0.8; -5.0 centimeters
Phase 2 N=20 Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
Prurigo Nodularis · Pruritus · Chronic Pruritus
Primary: Percent Change in Weekly Average Peak Pruritus Numeric Rating Scale (PP-NRS) From Baseline to Week 12 — -78.26; -53.66 percent change — p=<0.001
Phase 3 N=353 PRISM Study-Pruritus Relief Through Itch Scratch Modulation
Prurigo Nodularis
Primary: Percentage of Participants With ≥ 4- Point Decrease in 7-day Average Worst Itch - Numerical Rating Scale (WI-NRS) up to Week 14 — 24.24; 14.50 percentage of participants…
Phase 3 N=295 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
Pruritus · Prurigo Nodularis
Primary: Percent of Participants With Worst Itch Numeric Rating Scale (WI-NRS) 4-point Responder Rate at Week 10 — 18.95; 25.90; 81.05; 74.10 Percentage of participants — p=0.158
Phase 3 N=285 Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis
Pruritus · Prurigo Nodularis
Primary: Percent of Subjects With Worst-Itch Numeric Rating Scale 4-point Responder at Week 10 — 26.45; 20.31 Percentage of subjects — p=0.229
Phase 2 N=269 A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Chronic Kidney Diseases · Pruritus
Primary: Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score During Week 12 — -3.99; -3.84; -4.42; -3.32 score on…
Phase 3 N=160 Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)
Neurodermatitis
Primary: Percentage of Participants With Greater Than or Equal to (>=) 4 Points Improvement (Reduction) From Baseline in Worst-Itch Numeric Rating Scale (WI-NRS) Scores at Week…
Phase 2 N=111 The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) Trial
Chronic Kidney Disease-associated Pruritus
Primary: Mean Change in Weekly Mean Worst Itch Numeric Rating Score (WI-NRS) — -3.70; -3.87 score on a scale
Phase 3 N=151 Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)
Neurodermatitis
Primary: Percentage of Participants With Improvement (Reduction) in Worst Itch Numeric Rating Scale (WI-NRS) Scores by Greater Than or Equal to (>=) 4 Points From Baseline to…
Phase 2 N=69 Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
Treatment-resistant Pruritus Associated With Atopic Dermatitis
Primary: Change From Baseline to Endpoint (Day 28 or Early Termination) in Visual Analogue Scale (VAS) Pruritus 24 Hour Average Intensity. — -40.5; -36.5 mm
Phase 4 N=40 Management of Pruritus With Xyzal in Atopic Dermatitis
Atopic Dermatitis · Pruritus
Primary: Pruritus VAS Scores at Baseline, Week 2 and Week 4 — 7.8; 7.5; 6.10; 5.9 units on a scale
Phase 2 N=59 A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica
Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)
Primary: Percent Change From Baseline in Weekly Mean of the Daily 24-hour Worst Itch-Numeric Rating Scale (WI-NRS) Score at Week 4. — -44.37; -50.37 percentage of change from…
Phase 2 N=484 Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
Pruritus · Atopic Dermatitis
Primary: Change in WI-NRS From Baseline to Week 6 — -2.25; -2.32; -2.01 score on a scale
Phase 2 N=126 Treatment of Chronic Itch in Patients Under Arsenic Exposure With Naloxone
Chronic Pruritus
Primary: Numeric Rating Scale for Itch — 6.42; 7.8 score on a scale (0~10)
Phase 3 N=62 Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
Prurigo Nodularis · Nodularis Prurigo · Prurigo
Primary: Change From Baseline to the Evaluation Visit (Week 10) in Itch on the 0-10 Numerical Rating Scale — 27.3; 44.4; 36.4 percentage of subjects
Phase 2 N=168 Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
Atopic Dermatitis
Primary: Mean Change From Baseline in Pruritus Symptoms, as Measured by the 24-hour Average Pruritus Visual Analogue Scale (VAS) Score — -41.5; -35.8 score on a scale
Phase 3 N=175 Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Uremic Pruritus
Primary: Change From Baseline in the Weekly Mean of the Daily 24-hour Worst Itching Intensity NRS Score During Week 8 — -3.8; -2.8; -3.2; -1.9 score on a scale — p=<0.001
Phase 2 N=62 Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
Pruritus
Primary: Change From Baseline in the Worst Itch Numeric Rating Scale (WI-NRS) Score up to Week 6 — -2.20; -1.75 scores on a scale — p=0.4577
Phase 4 N=54 Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
Dermatitis Atopic
Primary: Change From Baseline in Intraepidermal Nerve Fiber Density on Lesional Skin at Week 17 — 8.4567; 4.2618 F/mm^2
Phase 3 N=258 To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Chronic Kidney Disease Associated Moderate to Severe Pruritus
Primary: Percentage of Responders With an Improvement of Worst Itch Numeric Rating Scale (WI NRS) Greater Than and Equal to (>=) 4 From Baseline at Week 12 — 38.5; 47.7; 32.4…
Phase 4 N=50 A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients
Pruritis
Primary: Severity of Pruritis — 10.88; 9.76; 6.64; 5.12 units on a scale
Phase 2 N=247 A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
Uremic Pruritus
Primary: Change From Baseline in the Mean NRS Score at Week 8 of the Treatment Period — -2.97; -3.65; -3.64; -2.86 points — p=0.770
Phase 2 N=5 Safety and Efficacy of CC-10004 for Prurigo Nodularis
Prurigo Nodularis
Primary: Improvement in Prurigo Nodularis — 0; 2 participants